Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. McDermott on Lessons From the IMmotion150 Trial in RCC

March 8th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

Petrylak Discusses Significance of Genetic Testing in Prostate Cancer

March 8th 2017

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Dr. Jonasch on First- and Second-line Options for Patients With RCC

March 8th 2017

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the advancements in the first- and second-line settings for treating patients with renal cell carcinoma (RCC). Jonasch shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Expert Discusses Promise of Immunotherapy in Genitourinary Cancers

March 8th 2017

Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.

Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer

March 8th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

Choueiri Discusses Papillary RCC, Other Developments in Kidney Cancer

March 7th 2017

Toni Choueiri, MD, discusses a study of the MET inhibitor savolitinib in papillary renal cell cancer as well as other exciting findings in kidney cancer.

Dr. Febbo Explains the Oncotype DX Genomic Prostate Score

March 7th 2017

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

A Call to Educate

March 4th 2017

Raoul S. Concepcion, MD, calls for increased oncology education and information sharing among the urology community across the globe, as urologists play a critical role in delivering and managing cancer treatment.

Dr. Drake on Immunotherapy Side Effects in Genitourinary Cancers

March 4th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.

Vaccine Shows Promise in Renal Cell Carcinoma

March 3rd 2017

Hans J. Hammers, MD, PhD, discusses early promising data for HyperAcute Renal immunotherapy in renal cell carcinoma and the overall potential for vaccines in the field.

Dr. Hammers Discusses Immunotherapy in RCC

March 2nd 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).

FDA Grants Avelumab Priority Review for Metastatic Urothelial Carcinoma

February 28th 2017

The FDA has granted a priority review to a biologics license application for avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Biomarkers Show Efficacy of Radium-223/Docetaxel Combo in mCRPC

February 28th 2017

Michael J. Morris, MD, discusses a phase I/II trial in which the combination of radium-223 (Xofigo) and docetaxel had a greater effect than docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer.

Dr. Choueiri on the Role of Traditional Agents in Kidney Cancer

February 27th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of traditional agents in the treatment of patients with kidney cancer.

Apolo Discusses Immunotherapy Advances in Bladder Cancer

February 25th 2017

Andrea Apolo, MD, discusses positive early trials exploring various regimens of nivolumab (Opdivo), ipilimumab (Yervoy), and avelumab in bladder cancer.

Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma

February 24th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

Dr. Linehan on Genes With Predisposition to Kidney Cancer

February 24th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.

Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers

February 23rd 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

McDermott Discusses Promising PD-L1/VEGF Combo Findings in Frontline mRCC

February 23rd 2017

David McDermott, MD, discusses the results and the significance of the IMmotion 150 trial in metastatic renal cell carcinoma.

Dendritic Immunotherapy Falters in Phase III RCC Trial

February 23rd 2017

An Independent Data Monitoring Committee has recommended halting the phase III ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma.